Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microperimetry and HD-OCT in Ranibizumab for DME (MORE)
NCT00885794Phase 3Unknown
- Sponsor
- Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
- Start
- May 2008
- Primary completion
- May 2011
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery. Primary endpoint: Retinal thickness at 3 months. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00885794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00885794.